Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
By M. Jun, Foote. The Lancet, 2010
643 citations recorded by the source corpus.
Subfields: Nutrition and Dietetics, Plant Science, Rheumatology
View Paper: https://www.semanticscholar.org/paper/fb053da612afe6e5a8fc4f116073bdb35b304ee4
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Nutrition and Dietetics
In Plant Science
In Rheumatology
Citations in the corpus
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, neutral): “Results from other meta-analyses suggest reduced major CVD events in patients with high TGs and low HDL-C in fibrate-treated patients, but no decrease in CVD or total mortality.(270) –272 Thus the overall efficacy of fibrates on CVD outcomes is much less robust than that of statins.”
- Guidelines for the Primary Prevention of Stroke (2011, neutral): “tion in the risk for major cardiovascular but no benefit on the risk of stroke (RR reduction, −3%; 95% CI, −16 to 9).(178)”
- “The Mediterranean Diet, its Components, and Cardiovascular Disease” (2014, neutral): “Estimates of lifestyle modifications such as the Mediterranean diet as a whole (106), fruits and vegetables (59, 61, 62), smoking cessation (103), moderate alcohol (105), omega-3 fatty acids (110), and improved physical activity (102) have substantial benefits for CVD prevention not seen with common”
- Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management (2011, neutral): “Results from individual monotherapy outcomes trials have been variable and primarily indicate a reduction in nonfatal MI and revascularization, with no effect on stroke or CV death, 207 subsequently confirmed by a meta-analysis.(208) Post hoc analyses of several of”
- Progress and challenges in translating the biology of atherosclerosis (2011, positive): “Fibrates effectively decrease triglyceride levels, but trials of these drugs have proven disappointing in reducing clinical events, and have not shown reductions in mortality rate”